Neuromuscular And Movement Disorders

SECTION 1

Historical Context & Motivation

The study of neuromuscular and movement disorders spans centuries of clinical observation, from the earliest descriptions of tremor in ancient medical texts to modern molecular characterizations of channelopathies and autoimmune syndromes. Understanding the historical evolution of this field illuminates why certain classification systems, diagnostic algorithms, and therapeutic strategies exist today. The clinical recognition that weakness, involuntary movements, and abnormal tone arise from distinct anatomic and physiologic lesion sites was a transformative concept that took generations of neurologists to establish. For the USMLE Step 2 candidate, appreciating this trajectory provides the conceptual scaffolding necessary to localize lesions, generate differential diagnoses, and select the most appropriate confirmatory tests and treatments in clinical vignettes.

1817

James Parkinson's Essay on the Shaking Palsy

James Parkinson published the first systematic clinical description of paralysis agitans, characterizing the resting tremor, festinating gait, and flexed posture that would eventually bear his name and become the archetype of basal ganglia disorders.

1868

Duchenne's Electrophysiological Studies

Guillaume-Benjamin-Amand Duchenne de Boulogne pioneered the use of electrical stimulation to study muscle physiology and described Duchenne muscular dystrophy, establishing the concept of primary myopathic disease distinct from neuropathy.

1895

Erb and Goldflam Describe Myasthenia Gravis

Wilhelm Erb and Samuel Goldflam independently characterized the fatigable weakness of myasthenia gravis, setting the stage for understanding neuromuscular junction pathology as a distinct entity.

1960s

Levodopa Revolutionizes Parkinson Treatment

Oleh Hornykiewicz demonstrated dopamine depletion in Parkinson disease, and Cotzias introduced high-dose levodopa therapy, transforming management and validating the dopaminergic hypothesis of movement disorders.

2000s–present

Genetic and Immunologic Precision

Advances in next-generation sequencing, autoantibody panels, and targeted immunotherapies have enabled precise molecular classification of neuromuscular disorders such as anti-MuSK myasthenia and genetically defined muscular dystrophies, ushering in an era of personalized neurology.

The central question this lesson addresses is one that USMLE Step 2 tests repeatedly: given a patient presenting with weakness, abnormal movement, or altered tone, how do you localize the lesion along the neuraxis—from the upper motor neuron through the basal ganglia, peripheral nerve, neuromuscular junction, and muscle—and then translate that localization into the correct diagnosis and management plan?

SECTION 2

Core Principles & Definitions

Effective clinical reasoning in neuromuscular and movement disorders rests on a small set of foundational principles. The motor system can be conceptualized as a hierarchy: upper motor neurons (UMNs) originating in cortex descend through the corticospinal tract, synapsing on lower motor neurons (LMNs) in the anterior horn. From there, the signal travels along peripheral nerves, crosses the neuromuscular junction (NMJ), and activates skeletal muscle fibers. In parallel, the basal ganglia and cerebellum modulate the initiation, amplitude, and coordination of voluntary movement. Disruption at any level produces characteristic patterns of signs and symptoms that allow precise anatomic localization.

UMN vs. LMN Lesion Patterns

UMN lesions produce spasticity, hyperreflexia, and an upgoing Babinski sign. LMN lesions produce flaccidity, hyporeflexia, fasciculations, and atrophy. Recognizing this dichotomy is the first step in every motor exam.

NMJ Pathology: Fatigable Weakness

Disorders of the neuromuscular junction—most importantly myasthenia gravis and Lambert-Eaton myasthenic syndrome (LEMS)—are characterized by weakness that worsens with repetitive use and improves with rest (or the reverse in LEMS).

Myopathies: Proximal, Symmetric Weakness

Primary muscle diseases—whether inflammatory, inherited, or metabolic—classically produce proximal, symmetric weakness without sensory deficits. Elevated creatine kinase (CK) is a hallmark laboratory finding.

Hypokinetic vs. Hyperkinetic Movement Disorders

Movement disorders are broadly divided into hypokinetic (e.g., Parkinson disease with bradykinesia, rigidity, tremor) and hyperkinetic (e.g., Huntington disease with chorea, dystonia, tics).

Peripheral Neuropathy Patterns

Peripheral neuropathies are classified by distribution (stocking-glove vs. mononeuropathy multiplex), fiber type (motor vs. sensory vs. autonomic), and pathology (demyelinating vs. axonal), each pattern narrowing the differential diagnosis.

✦ KEY TAKEAWAY

Think of the motor system as an electrical circuit from a power plant (cortex) through high-voltage transmission lines (corticospinal tract) to a local transformer (anterior horn cell), household wiring (peripheral nerve), a switch (NMJ), and finally the appliance (muscle). A fault at any point produces a predictable, recognizable failure pattern—just as a tripped breaker produces different symptoms than a frayed wire or a burned-out motor. Basal ganglia and cerebellar circuits act like the software control system regulating when and how power flows, and their dysfunction manifests as abnormal movement programs rather than simple weakness.

SECTION 3

Visual Explanation: Neuroanatomic Localization

This diagram traces the motor pathway from the motor cortex (UMN) through the anterior horn cell (LMN), peripheral nerve, neuromuscular junction, and skeletal muscle. The characteristic clinical findings at each lesion level are annotated laterally. Note that the basal ganglia modulate movement quality rather than producing weakness per se.

The diagram above represents the fundamental framework for approaching any USMLE Step 2 neuromuscular question. When presented with weakness, your first task is to determine where along this pathway the lesion lies. A patient with bilateral lower extremity weakness, hyperreflexia, and Babinski signs localizes to the UMN—perhaps a spinal cord lesion. In contrast, a patient with bilateral lower extremity weakness, areflexia, and stocking-glove sensory loss localizes to the peripheral nerves, consistent with Guillain-Barré syndrome or a chronic polyneuropathy. This vertical localization scheme applies uniformly across the breadth of neuromuscular pathology and is the single most powerful organizational tool for exam preparation.

SECTION 4

Pathophysiologic Mechanisms

Neuromuscular Junction: Autoimmune Disruption

In myasthenia gravis (MG), IgG autoantibodies target the postsynaptic acetylcholine receptor (AChR), causing complement-mediated destruction and internalization of receptors. The net effect is a reduction in the number of functional AChRs, resulting in a decremental response on repetitive nerve stimulation (RNS). With each successive nerve impulse, fewer quanta of acetylcholine (ACh) are released (physiologic rundown), and with fewer receptors available, the end-plate potential fails to reach threshold—producing the hallmark fatigable weakness that worsens with sustained or repeated activity.

In contrast, Lambert-Eaton myasthenic syndrome (LEMS) involves antibodies against presynaptic voltage-gated calcium channels (VGCCs). Reduced calcium influx into the presynaptic terminal diminishes ACh release. With rapid repetitive stimulation, calcium accumulates in the terminal, partially overcoming the block and producing an incremental response (post-exercise facilitation). LEMS is frequently paraneoplastic, most commonly associated with small cell lung carcinoma.

Peripheral Neuropathy: Demyelinating vs. Axonal

Peripheral neuropathies are dichotomized electrophysiologically into demyelinating and axonal subtypes. Demyelinating neuropathies—exemplified by Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP)—show slowed nerve conduction velocities, prolonged distal latencies, temporal dispersion, and conduction block on nerve conduction studies (NCS). Axonal neuropathies, such as diabetic peripheral neuropathy, demonstrate reduced compound muscle action potential (CMAP) and sensory nerve action potential (SNAP) amplitudes with relatively preserved conduction velocities. This distinction is clinically important because demyelinating neuropathies are often immune-mediated and potentially treatable with IVIG or plasmapheresis, whereas axonal neuropathies more commonly reflect metabolic, toxic, or hereditary etiologies.

Basal Ganglia Circuitry: Direct and Indirect Pathways

The basal ganglia regulate movement through two parallel circuits. The direct pathway (striatum → GPi/SNr, using D1 receptors) facilitates movement by disinhibiting the thalamus. The indirect pathway (striatum → GPe → STN → GPi/SNr, using D2 receptors) suppresses unwanted movement by increasing thalamic inhibition. In Parkinson disease, loss of dopaminergic neurons in the substantia nigra pars compacta reduces direct pathway activation (via D1) and reduces indirect pathway inhibition (via D2), resulting in net excessive inhibition of the thalamus and the cardinal features of bradykinesia, rigidity, and resting tremor. In Huntington disease, early degeneration of the indirect pathway's striatal neurons leads to reduced thalamic inhibition and excessive, unwanted movement (chorea).

💡 Clinical Pearl

The mnemonic for Parkinson disease cardinal features is TRAP: Tremor (resting), Rigidity (cogwheel), Akinesia/bradykinesia, and Postural instability. The most specific feature for diagnosis is bradykinesia.

SECTION 5

Classification of Key Disorders

This classification tree organizes neuromuscular and movement disorders by anatomic localization. Neuromuscular disorders (neuropathies, NMJ diseases, myopathies) are on the left; movement disorders (hypokinetic and hyperkinetic) are on the right. Motor neuron diseases bridge both categories, with ALS being the prototypical combined UMN/LMN disorder.

High-Yield Neuromuscular and Movement Disorders for USMLE Step 2

Disorder	Key Clinical Features	Diagnostic Test	Treatment
Myasthenia Gravis	Fatigable ptosis, diplopia; worse in PM; bulbar weakness	AChR Ab (85%), anti-MuSK Ab; RNS (decremental); CT chest for thymoma	Pyridostigmine, immunosuppression, thymectomy; IVIG/PLEX for crisis
Lambert-Eaton (LEMS)	Proximal weakness improving with activity; areflexia; autonomic dysfunction	VGCC Ab; RNS (incremental); screen for SCLC	3,4-DAP; treat underlying malignancy; immunosuppression
Guillain-Barré (GBS)	Ascending weakness, areflexia; post-infectious; albuminocytologic dissociation in CSF	NCS (demyelinating); LP (↑ protein, normal WBC)	IVIG or plasmapheresis; supportive (monitor FVC)
ALS	Combined UMN + LMN signs; fasciculations; no sensory loss; tongue atrophy	EMG (diffuse denervation); El Escorial criteria	Riluzole (modest survival benefit); edaravone; supportive care
Parkinson Disease	Resting tremor, bradykinesia, cogwheel rigidity, postural instability; asymmetric onset	Clinical diagnosis; DaTscan if uncertain; MRI to exclude structural lesions	Levodopa/carbidopa; dopamine agonists; MAO-B inhibitors; deep brain stimulation
Huntington Disease	Chorea, psychiatric symptoms, dementia; autosomal dominant; onset 30s–50s	Genetic testing (CAG repeat ≥ 36 on HTT gene); MRI: caudate atrophy	Tetrabenazine/deutetrabenazine (chorea); antipsychotics; supportive

SECTION 6

Worked Clinical Vignette

The following worked example walks through a classic USMLE-style clinical vignette step by step, demonstrating the systematic approach to neuromuscular localization and diagnosis.

Case: A 28-Year-Old Woman with Progressive Weakness

Step 1 — Identify the Clinical PresentationA 28-year-old woman presents with 5 days of progressive bilateral leg weakness that began in her feet and has ascended to involve her thighs. She reports tingling in her fingers and toes. Ten days ago, she had a self-limited diarrheal illness. On exam, she has 3/5 strength in her lower extremities, 4/5 in her upper extremities, absent deep tendon reflexes bilaterally, and intact cranial nerves. Toes are downgoing. Sensory exam reveals decreased vibratory sense in the feet.

Ascending weakness + areflexia + post-infectious onset

Step 2 — Localize the LesionThe combination of bilateral, symmetric, ascending weakness with areflexia points to a lower motor neuron (LMN) process. The absence of UMN signs (no spasticity, no Babinski) excludes a cord lesion. Sensory involvement excludes a pure NMJ or myopathic process. The pattern is consistent with a peripheral polyneuropathy affecting motor > sensory fibers.

Localization: peripheral nerves (polyradiculoneuropathy)

Step 3 — Generate the Differential DiagnosisGiven the acute-subacute onset, ascending pattern, post-infectious trigger (likely Campylobacter jejuni diarrheal illness), and areflexia, the leading diagnosis is Guillain-Barré syndrome (acute inflammatory demyelinating polyneuropathy — AIDP). Other considerations include transverse myelitis (but UMN signs are absent), acute intermittent porphyria, and tick paralysis.

Top diagnosis: Guillain-Barré syndrome (AIDP)

Step 4 — Confirm with Appropriate WorkupThe two key confirmatory studies are: (1) lumbar puncture showing albuminocytologic dissociation (elevated protein with a normal cell count, typically < 10 WBCs/μL), and (2) nerve conduction studies demonstrating slowed conduction velocities, prolonged distal latencies, and conduction block consistent with demyelination. Note that CSF findings and NCS may be normal in the first few days; serial testing may be needed.

LP: ↑ protein, normal WBC | NCS: demyelinating pattern

Step 5 — Initiate ManagementTreatment includes either IVIG or plasmapheresis (both are equally effective; combining them confers no additional benefit). Critically, monitor forced vital capacity (FVC) and negative inspiratory force (NIF) serially. Intubation is indicated if FVC < 20 mL/kg or NIF is weaker than −30 cmH₂O. Corticosteroids are NOT effective in GBS (in contrast to CIDP, where they are first-line). DVT prophylaxis is also important given immobility.

IVIG or plasmapheresis; monitor FVC; NO steroids in GBS

SECTION 7

High-Yield Diagnostic Comparisons

Myasthenia Gravis vs. Lambert-Eaton Myasthenic Syndrome

MG vs. LEMS: Key Differentiating Features

Feature	Myasthenia Gravis	Lambert-Eaton (LEMS)
Antibody Target	Postsynaptic AChR (or MuSK)	Presynaptic VGCC
Pattern of Weakness	Ocular/bulbar predominant → generalized; worsens with activity	Proximal limbs predominant; improves transiently with activity
Reflexes	Normal	Absent/diminished; may improve post-exercise
Autonomic Symptoms	Absent	Dry mouth, constipation, impotence
RNS Pattern	Decremental at low-frequency stimulation	Incremental at high-frequency stimulation
Associated Malignancy	Thymoma (10–15%)	Small cell lung cancer (~60%)
Treatment	Pyridostigmine, immunosuppression, thymectomy	3,4-DAP, treat tumor, immunosuppression

Parkinson Disease vs. Parkinson-Plus Syndromes

Distinguishing Idiopathic PD from Parkinson-Plus Syndromes

Feature	Idiopathic PD	MSA	PSP
Tremor	Prominent resting tremor	Less prominent	Rare
Symmetry	Asymmetric onset	Often symmetric	Often symmetric
Levodopa Response	Excellent (early)	Poor or transient	Poor
Distinguishing Feature	Classic TRAP features	Cerebellar ataxia or severe autonomic failure	Vertical supranuclear gaze palsy; early falls
Pathology	Lewy bodies (α-synuclein)	Glial cytoplasmic inclusions (α-synuclein)	Neurofibrillary tangles (tau)

✦ KEY TAKEAWAY

For USMLE purposes, the single most important distinguishing feature between idiopathic Parkinson disease and Parkinson-plus syndromes is the response to levodopa. Idiopathic PD shows a robust early response, while MSA, PSP, and corticobasal degeneration show poor or absent responses. Think of levodopa responsiveness as the litmus test: if the patient does not improve with adequate levodopa dosing, reconsider the diagnosis. Similarly, the presence of early, prominent red flags—early falls (PSP), severe autonomic failure (MSA), or alien limb phenomenon (CBD)—should prompt you to question a diagnosis of idiopathic PD.

SECTION 8

Connections to Advanced Neurology & Emerging Therapies

While USMLE Step 2 focuses on clinical recognition and first-line management, an understanding of the advanced and evolving landscape strengthens clinical reasoning and prepares you for more nuanced patient encounters on the wards. Several developments are reshaping how neuromuscular and movement disorders are classified and treated.

From Step 2 Foundations to Advanced Therapeutics

Standard Step 2 Knowledge	Emerging / Advanced Concept
MG diagnosed by AChR Ab; treated with pyridostigmine	Complement inhibitors (eculizumab, ravulizumab) and FcRn antagonists (efgartigimod) provide targeted immunotherapy for refractory MG, reducing steroid burden
GBS managed with IVIG or plasmapheresis	Anti-ganglioside antibody panels (e.g., anti-GQ1b in Miller Fisher variant) enable serotype-specific diagnosis; biomarkers predicting respiratory failure are under investigation
Duchenne dystrophy = dystrophin gene mutation; supportive care	Exon-skipping therapies (eteplirsen, viltolarsen) and gene replacement therapy (delandistrogene moxeparvovec) represent paradigm shifts toward molecular correction
Parkinson disease treated with levodopa/carbidopa	Alpha-synuclein–targeting immunotherapies, GBA1-targeted substrate reduction, and continuous subcutaneous levodopa infusions are in late-phase trials
SMA = SMN1 gene deletion; historically fatal	Nusinersen (antisense oligonucleotide), onasemnogene abeparvovec (gene therapy), and risdiplam (small molecule) have dramatically altered natural history when given early

These advances highlight a recurring theme: as the molecular basis of neuromuscular and movement disorders becomes more precisely defined, therapy shifts from supportive and broadly immunosuppressive to targeted, mechanism-based interventions. For Step 2 preparation, your task is to master the foundational presentations, diagnostic workups, and established treatments—but awareness of the therapeutic frontier will serve you well in clinical clerkships and beyond.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A patient presents with weakness that worsens with repeated use throughout the day and is worst in the evening. Deep tendon reflexes are normal. There is no sensory deficit. Where along the motor pathway is the lesion most likely localized, and what is the most probable diagnosis?

PROBLEM 2 — BASIC CALCULATION

A 45-year-old man with Guillain-Barré syndrome has the following pulmonary function values obtained at the bedside: forced vital capacity (FVC) = 1.2 L; his weight is 80 kg. Calculate the FVC in mL/kg and determine whether intubation is indicated based on the commonly used threshold.

PROBLEM 3 — INTERMEDIATE

A 62-year-old man with a 40-pack-year smoking history presents with proximal lower extremity weakness, dry mouth, and constipation. Reflexes are absent in the lower extremities but can be elicited after 10 seconds of sustained isometric quadriceps contraction. What is the most likely diagnosis, and what cancer screening should be prioritized?

PROBLEM 4 — APPLIED

A 55-year-old woman presents with a 1-year history of progressive difficulty walking, frequent falls, and slurred speech. Examination reveals bradykinesia, axial rigidity greater than limb rigidity, and restriction of voluntary downward gaze. She has minimal resting tremor. A trial of carbidopa-levodopa produces no improvement. What is the most likely diagnosis, and what pathologic findings would be expected on autopsy?

PROBLEM 5 — CRITICAL THINKING

A 70-year-old man presents with 6 months of progressive weakness affecting his right hand and left leg. Examination reveals fasciculations in multiple limbs, tongue fasciculations with atrophy, hyperreflexia in the left lower extremity, and an extensor plantar response on the left. Sensory examination is entirely normal. EMG shows acute and chronic denervation in cervical, thoracic, and lumbosacral myotomes. Explain why the coexistence of both upper and lower motor neuron signs in multiple regions—without sensory involvement—strongly points toward one specific diagnosis. What alternative diagnoses must be excluded, and why?

SUMMARY

Lesson Summary

Neuromuscular and movement disorders are approached through systematic lesion localization along the motor pathway. UMN lesions produce spasticity, hyperreflexia, and Babinski signs, while LMN lesions produce flaccidity, areflexia, fasciculations, and atrophy. Neuromuscular junction disorders (MG and LEMS) present with fatigable weakness; MG shows a decremental response due to postsynaptic AChR antibodies, while LEMS shows an incremental response due to presynaptic VGCC antibodies (screen for small cell lung cancer). Guillain-Barré syndrome is an acute demyelinating polyradiculoneuropathy treated with IVIG or plasmapheresis—not steroids—with serial FVC monitoring to prevent respiratory failure. ALS is identified by combined UMN and LMN signs without sensory involvement across multiple body regions.

Among movement disorders, Parkinson disease (TRAP: tremor, rigidity, akinesia, postural instability) is the prototypical hypokinetic disorder, treated with levodopa/carbidopa. A robust levodopa response distinguishes it from Parkinson-plus syndromes (MSA, PSP, CBD) which are levodopa-refractory. Huntington disease is the classic hyperkinetic disorder (autosomal dominant, CAG trinucleotide repeat, caudate atrophy), treated symptomatically with tetrabenazine. For every clinical vignette, the approach should be: localize → generate differential → confirm with appropriate workup → initiate evidence-based management.